PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för zibotentan. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

31 hits

Bibliografisk träff 2024-04-30

Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.

Mercier AK, Kois AK, Karsanji D, Baldry R, Birve F, Hedwall M, Molodetskyi O, Gillen M.

Clin Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.1002/cpt.3280

Bibliografisk träff 2024-03-24

A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.

Fettiplace A, Matis-Mitchell S, Molodetskyi O, Söderbergh M, Oscarsson J, Lin M, Ravikiran S, Billger M, Ambery P.

Expert Opin Drug Saf · journal article · DOI 10.1080/14740338.2024.2328816

Bibliografisk träff 2024-02-27

Anti-Anginal Efficacy of Zibotentan in the Coronary Slow-Flow Phenomenon.

Pasupathy S, Tavella R, Zeitz C, Edwards S, Worthley M, Arstall M, Beltrame JF.

J Clin Med · research-article; journal article · DOI 10.3390/jcm13051337

Bibliografisk träff 2024-02-01

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.

Heerspink HJL, Greasley PJ, Ahlström C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnåker M, Turton M, Wheeler DC, Ambery P.

Nephrol Dial Transplant · clinical trial protocol; research-article; journal article · DOI 10.1093/ndt/gfad183

Bibliografisk träff 2023-12-18

Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity.

Nakamura T, Okumura M, Takamune N, Hirotsu T, Sugiura M, Yasunaga J, Nakata H.

PNAS Nexus · research-article; journal article · DOI 10.1093/pnasnexus/pgad446

Bibliografisk träff 2023-11-03

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.

Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P.

Lancet · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)02230-4

Bibliografisk träff 2023-10-06

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.

Mercier AK, Sunnåker M, Ueckert S, Pawlik T, Henricson E, Molodetskyi O, Law GC, Parker VER, Oscarsson J.

Clin Pharmacokinet · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s40262-023-01306-7

Bibliografisk träff 2023-09-01

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.

Veenit V, Heerspink HJL, Ahlström C, Greasley PJ, Skritic S, van Zuydam N, Kohan DE, Hansen PBL, Menzies RI.

Nephrol Dial Transplant · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/ndt/gfad078

Bibliografisk träff 2022-06-01

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.

Stern EP, Host LV, Wanjiku I, Escott KJ, Gilmour PS, Ochiel R, Unwin R, Burns A, Ong VH, Cadiou H, O'Keeffe AG, Denton CP.

Arthritis Res Ther · letter; clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial · DOI 10.1186/s13075-022-02818-6

Bibliografisk träff 2022-02-25

Mechanistic study of the effect of Endothelin SNPs in microvascular angina - Protocol of the PRIZE Endothelin Sub-Study.

Abraham GR, Morrow AJ, Oliveira J, Weir-McCall JR, Davenport EE, Berry C, Davenport AP, Hoole SP.

Int J Cardiol Heart Vasc · research-article; journal article · DOI 10.1016/j.ijcha.2022.100980

Bibliografisk träff 2020-09-01

Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.

Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R, McEntegart M, Maguire JJ, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sattar N, Hsu LY, Arai AE, Oldroyd KG, Touyz RM, Davenport AP, Berry C.

Eur Heart J · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/eurheartj/ehz915

Bibliografisk träff 2020-07-17

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.

Morrow AJ, Ford TJ, Mangion K, Kotecha T, Rakhit R, Galasko G, Hoole S, Davenport A, Kharbanda R, Ferreira VM, Shanmuganathan M, Chiribiri A, Perera D, Rahman H, Arnold JR, Greenwood JP, Fisher M, Husmeier D, Hill NA, Luo X, Williams N, Miller L, Dempster J, Macfarlane PW, Welsh P, Sattar N, Whittaker A, Connachie AM, Padmanabhan S, Berry C.

Am Heart J · clinical trial protocol; research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.ahj.2020.07.007

Bibliografisk träff 2020-01-01

Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion.

Palmer JC, Tayler HM, Dyer L, Kehoe PG, Paton JFR, Love S.

J Alzheimers Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.3233/jad-190630

Bibliografisk träff 2019-08-01

Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone Metastasis.

Moon HH, Clines KL, Cooks MA, Cialek CA, Esvelt MA, Clines GA.

Endocrinology · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1210/en.2019-00261

Bibliografisk träff 2019-04-02

Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.

Shen W, Xi H, Li C, Bian S, Cheng H, Cui J, Wang N, Wei B, Huang X, Chen L.

Ann N Y Acad Sci · research support, non-u.s. gov't; journal article · DOI 10.1111/nyas.14053

Bibliografisk träff 2018-12-30

The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells.

Esvelt MA, Freeman ZT, Pearson AT, Harkema JR, Clines GT, Clines KL, Dyson MC, Hoenerhoff MJ.

Toxicol Pathol · research-article; journal article · DOI 10.1177/0192623318816295

Bibliografisk träff 2017-01-31

Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Moody TW, Ramos-Alvarez I, Moreno P, Mantey SA, Ridnour L, Wink D, Jensen RT.

Peptides · research-article; journal article · DOI 10.1016/j.peptides.2017.01.012

Bibliografisk träff 2013-05-30

Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study.

Haque SU, Dashwood MR, Heetun M, Shiwen X, Farooqui N, Ramesh B, Welch H, Savage FJ, Ogunbiyi O, Abraham DJ, Loizidou M.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-12-0975

Bibliografisk träff 2013-04-08

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.

J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2012.46.4149

Bibliografisk träff 2013-02-05

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.

Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.

Prostate Cancer Prostatic Dis · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1038/pcan.2013.2

Bibliografisk träff 2012-12-09

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K.

Gynecol Oncol · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ygyno.2012.12.004

Bibliografisk träff 2012-07-11

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.

Cancer · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cncr.27674

Bibliografisk träff 2012-05-22

Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.

Li J, Liu Y, Qian J, Wu L, Kemp J, Nii M, Tomkinson H, Zuo Y, Ranson M, Usami M.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1870-6

Bibliografisk träff 2011-10-20

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H.

Xenobiotica · journal article · DOI 10.3109/00498254.2011.624204

Bibliografisk träff 2011-06-10

The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs.

Clarkson-Jones JA, Kenyon AS, Tomkinson HK.

Xenobiotica · research support, non-u.s. gov't; journal article · DOI 10.3109/00498254.2011.562565

Bibliografisk träff 2011-03-17

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.

Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.

BMC Clin Pharmacol · clinical trial; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1186/1472-6904-11-3

Bibliografisk träff 2011-03-12

The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feed.

Lenz EM, Kenyon A, Martin S, Temesi D, Clarkson-Jones J, Tomkinson H.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2011.02.005

Bibliografisk träff 2011-01-26

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA, Nathan F, Taboada M, Morris T, Hubner A.

Prostate · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/pros.21342

Bibliografisk träff 2010-11-01

Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.

Ranson M, Wilson RH, O'Sullivan JM, Maruoka M, Yamaguchi A, Cowan RA, Logue JP, Tomkinson H, Tominaga N, Swaisland H, Oliver S, Usami M.

Int J Clin Pharmacol Ther · multicenter study; journal article · DOI 10.5414/cpp48708

Bibliografisk träff 2009-09-19

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R.

Invest New Drugs · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-009-9318-5